Publication of Final Terms for €800m bond offering
The Final Terms, dated 1 June 2021, relating to the issue by AstraZeneca PLC of €800,000,000 of fixed rate notes with a coupon of 0.375%, maturing on 3 June 2029 (the 'Notes') are available for viewing.
The Notes will be issued under the $10,000,000,000 EMTN programme of AstraZeneca PLC and AstraZeneca Finance LLC. The Final Terms must be read in conjunction with the Base Prospectus dated 24 May 2021.
To view the Final Terms for the Notes, please paste the following URL into the address bar of your browser:http://www.rns-pdf.londonstockexchange.com/rns/5008A_1-2021-6-1.pdf
A copy of the above Final Terms will shortly be available for inspection at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 02 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2021 10:26:01 UTC.